Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 2,366 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Challenge Study of an ETEC Vaccine

NCT01922856
View directory record Official record
Conditions
Enteritis; Escherichia Coli, Enterotoxigenic
Interventions
LTR192G with dscCfaE, No Intervention
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Not applicable Interventional

Clinical Decision Support Tool for Vancomycin Dosing in Children

NCT04911270
View directory record Official record
Conditions
Gram-Positive Bacterial Infections, Vancomycin, Pharmacokinetics, Pharmacodynamics
Interventions
Computer Decision Support Tool Intervention Group, Matched Historical Controls
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 3 Interventional

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677569
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 2 Interventional

Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection

NCT00772343
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile Infection
Interventions
0.9% Normal Saline, Clostridium difficile toxoid vaccine, Clostridium difficile toxoid vaccine with adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Tampa, Florida • Marietta, Georgia • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 27, 2026, 10:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Data Bank Creation to Study Vaginal Conditions

NCT01829204
View directory record Official record
Conditions
Vulvodynia, Mycoses, Bacterial Vaginosis, Preterm Labor
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Midland, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

NCT05526716
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, QIV, Matching Placebo for V116
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
56
States / cities
Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin

NCT03718806
View directory record Official record
Conditions
Gonorrhea
Interventions
Zoliflodacin, high calorie, high fat breakfast
Drug · Other
Lead sponsor
Drugs for Neglected Diseases
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05620836
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
38
States / cities
Scottsdale, Arizona • Arkansas City, Arkansas • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 27, 2026, 10:55 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Vaginal Ecosystem and Network in the United States Study

NCT06472765
View directory record Official record
Conditions
Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause, Lichen Sclerosus, Lichen Planus, Vulvodynia, Endometriosis, Ureaplasma Infections, Cancer, Desquamative Inflammatory Vaginitis
Interventions
Vaginal Swab Collection
Diagnostic Test
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
3,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Pasadena, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 27, 2026, 10:55 PM EDT
Withdrawn No phase listed Observational

Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children

NCT00645619
View directory record Official record
Conditions
Viral Pneumonia, Bacterial Pneumonia
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

NCT00037219
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

NCT00002019
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Amphotericin B, Lipid-based, Amphotericin B
Drug
Lead sponsor
Liposome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Torrance, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

NCT00638365
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
KB001, Placebo
Biological · Other
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 1 Interventional

A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS

NCT00000992
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Itraconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 27, 2026, 10:55 PM EDT
Withdrawn No phase listed Observational

Video Based Directly Observed Therapy for Latent TB

NCT03783728
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine 600 mg orally, Isoniazid 900 mg orally, Pyridoxine 50 mg orally
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 27, 2026, 10:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of the Click Sexual Health Test for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women

NCT04098900
View directory record Official record
Conditions
Chlamydial Infection, Gonococcal Infection, Trichomoniasis
Interventions
Click Sexual Health Test
Diagnostic Test
Lead sponsor
Visby Medical
Industry
Eligibility
14 Years to 99 Years · Female only
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Saint Paul, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 27, 2026, 10:55 PM EDT
Withdrawn Early Phase 1 Interventional

Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.

NCT04084665
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Guselkumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 27, 2026, 10:55 PM EDT
Terminated Phase 2 Interventional Results available

The Clostridioides Difficile Trial of REC-3964

NCT06536465
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection
Interventions
REC-3964
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 115 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Toms River, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 27, 2026, 10:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Biological Characteristics of Hidradenitis Suppurativa

NCT03967600
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

NCT00077675
View directory record Official record
Conditions
Infections, Gram-positive Bacterial
Interventions
Telavancin, vancomycin or antistaphylococcal penicillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 27, 2026, 10:55 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

NCT07425392
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, PCV20
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
30
States / cities
Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 27, 2026, 10:55 PM EDT
Recruiting Phase 2 Interventional

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

NCT07783542
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
ORKA-002, Placebo
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 27, 2026, 10:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

NCT04309656
View directory record Official record
Conditions
Multi-drug Resistant Tuberculosis
Interventions
Pretomanid
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 27, 2026, 10:55 PM EDT